التفاصيل البيبلوغرافية
العنوان:
Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma
المؤلفون:
Judith S. Kaur , Jacob B. Allred , Wendy K. Nevala , Domingo G. Perez , Timothy D. Moore , Svetomir N. Markovic , Edward T. Creagan , Michael A. Thompson , Elizabeth Ann T. Lieser , Benjamin T. Marchello , Barbara A. Pockaj , Roxana S. Dronca , William J. Maples
المصدر:
American Journal of Clinical Oncology . 37:369-376
بيانات النشر:
Ovid Technologies (Wolters Kluwer Health), 2014.
سنة النشر:
2014
مصطلحات موضوعية:
Adult , Male , Vascular Endothelial Growth Factor A , Cancer Research , Skin Neoplasms , Dacarbazine , Article , Disease-Free Survival , Antineoplastic Combined Chemotherapy Protocols , Temozolomide , medicine , Humans , PTEN , Everolimus , Melanoma , PI3K/AKT/mTOR pathway , Aged , Aged, 80 and over , Sirolimus , biology , business.industry , TOR Serine-Threonine Kinases , Induction Chemotherapy , Middle Aged , medicine.disease , Temsirolimus , Treatment Outcome , Oncology , Tumor progression , Immunology , Cancer research , biology.protein , Female , business , medicine.drug
الوصف:
The management of patients with metastatic melanoma remains a difficult problem. Although potentially curable when diagnosed early, the median survival of patients with metastatic disease is generally
تدمد:
0277-3732
DOI:
10.1097/coc.0b013e31827b45d4
URL الوصول:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20d54871bf7f96148c6f85b4fbe560b8 https://doi.org/10.1097/coc.0b013e31827b45d4
Rights:
OPEN
رقم الانضمام:
edsair.doi.dedup.....20d54871bf7f96148c6f85b4fbe560b8
قاعدة البيانات:
OpenAIRE